Autologous cells derived from different sources and administered using different regimens for 'no-option' critical lower limb ischaemia patients

Fadilah, S A W; Ismail, Nor Azimah; Jamaludin, Wan Fariza Wan; Muhamad, Nor Asiah; Hamid, Muhammad Khairul Azaham Abdul; Harunarashid, Hanafiah; Lai, Nai Ming

doi:10.1002/14651858.cd010747.pub2

Cited by 32 publications

(38 citation statements)

References 140 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In recent years, a large number of clinical trials have shown a positive effect of new treatment modality using regenerative potential of the autologous stem cells transplantation [ 4 ]. In 2017, a meta-analysis by Guo et al reported the effect of autologous stem cell administration in the treatment of diabetic foot ulcer [ 5 ].…”

Section: Introductionmentioning

confidence: 99%

Treatment of Diabetic Foot with Autologous Stem Cells: A Meta-Analysis of Randomized Studies

Dai

Jiang

Chen

et al. 2020

Stem Cells International

View full text Add to dashboard Cite

Background. This meta-analysis was to evaluate the efficacy of autologous stem cell administration for the treatment of diabetic foot. Methods. The electronic databases included PubMed, EMBASE, BIOSIS, Cochrane central, and Google Scholar internet, last updated on May 30, 2019. Evaluated outcomes included the rate of wound healing and amputation. Dichotomous outcomes were described as risk ratios (RR) with 95% confidence intervals (CIs). Statistical analysis was performed with RevMan 5.0 software and STATA 10.0 software. Results. Eight randomized controlled trial (RCT) studies were included in this study. The meta-analysis showed a lower amputation (RR 0.25, 95% CI 0.11 to 0.54, I2=0) and a higher wound healing rate (RR 2.05, 95% CI 1.67 to 2.51, I2=4) in the cell therapy group compared with control. Conclusion. This meta-analysis supports the effective role of stem cell therapy in promoting wound healing and decreasing rate of amputation in diabetic foot. In the future, more high quality and well-designed studies are need.

show abstract

Section: Introductionmentioning

confidence: 99%

Treatment of Diabetic Foot with Autologous Stem Cells: A Meta-Analysis of Randomized Studies

Dai

Jiang

Chen

et al. 2020

Stem Cells International

View full text Add to dashboard Cite

show abstract

“…ADSC are considered the most promising cell source for cell therapy because of their regenerative capacity due to secretion of pro-survival soluble factors, production of extracellular matrix proteins, and their immunomodulating properties [20,21]. However, results of numerous cell therapy clinical trials, including those with ADSC, did not meet initial expectations [22,23]. In those studies, conventionally used direct injections of cell suspensions showed limited efficacy, putatively due to low cell viability as a result of cell-to-cell interaction loss, compression damage during administration by injection, and the unfavorable microenvironment in ischemic and inflammatory tissue.…”

Section: Discussionmentioning

confidence: 99%

Transplantation of Adipose Stromal Cell Sheet Producing Hepatocyte Growth Factor Induces Pleiotropic Effect in Ischemic Skeletal Muscle

Boldyreva

Shevchenko

Molokotina

et al. 2019

IJMS

View full text Add to dashboard Cite

Cell therapy remains a promising approach for the treatment of cardiovascular diseases. In this regard, the contemporary trend is the development of methods to overcome low cell viability and enhance their regenerative potential. In the present study, we evaluated the therapeutic potential of gene-modified adipose-derived stromal cells (ADSC) that overexpress hepatocyte growth factor (HGF) in a mice hind limb ischemia model. Angiogenic and neuroprotective effects were assessed following ADSC transplantation in suspension or in the form of cell sheet. We found superior blood flow restoration, tissue vascularization and innervation, and fibrosis reduction after transplantation of HGF-producing ADSC sheet compared to other groups. We suggest that the observed effects are determined by pleiotropic effects of HGF, along with the multifactorial paracrine action of ADSC which remain viable and functionally active within the engineered cell construct. Thus, we demonstrated the high therapeutic potential of the utilized approach for skeletal muscle recovery after ischemic damage associated with complex tissue degenerative effects.

show abstract

“…The clinical data about these cells have demonstrated they are safe and well-tolerated in patients. In terms of cell efficacy, current trials are very dissimilar, and this makes comparison of their results difficult, because these autologous cells have been derived from various sources, prepared using distinctive protocols, administered at different doses, and delivered via diverse routes [ 20 ]. In particular, the efficiency of cell therapy on clinical end points is not as great as it was in preclinical trials in the randomized controlled trials [ 21 , 22 ].…”

Section: Pathophysiology Of Pad and Brief Overview Of Current Clinicamentioning

confidence: 99%

Bioengineering strategies for the treatment of peripheral arterial disease

Kitzerow

Nie

et al. 2021

Bioactive Materials

View full text Add to dashboard Cite

Peripheral arterial disease (PAD) is a progressive atherosclerotic disorder characterized by narrowing and occlusion of arteries supplying the lower extremities. Approximately 200 million people worldwide are affected by PAD. The current standard of operative care is open or endovascular revascularization in which blood flow restoration is the goal. However, many patients are not appropriate candidates for these treatments and are subject to continuous ischemia of their lower limbs. Current research in the therapy of PAD involves developing modalities that induce angiogenesis, but the results of simple cell transplantation or growth factor delivery have been found to be relatively poor mainly due to difficulties in stem cell retention and survival and rapid diffusion and enzymolysis of growth factors following injection of these agents in the affected tissues. Biomaterials, including hydrogels, have the capability to protect stem cells during injection and to support cell survival. Hydrogels can also provide a sustained release of growth factors at the injection site. This review will focus on biomaterial systems currently being investigated as carriers for cell and growth factor delivery, and will also discuss biomaterials as a potential stand-alone method for the treatment of PAD. Finally, the challenges of development and use of biomaterials systems for PAD treatment will be reviewed.

show abstract

Autologous cells derived from different sources and administered using different regimens for 'no-option' critical lower limb ischaemia patients

Cited by 32 publications

References 140 publications

Treatment of Diabetic Foot with Autologous Stem Cells: A Meta-Analysis of Randomized Studies

Treatment of Diabetic Foot with Autologous Stem Cells: A Meta-Analysis of Randomized Studies

Transplantation of Adipose Stromal Cell Sheet Producing Hepatocyte Growth Factor Induces Pleiotropic Effect in Ischemic Skeletal Muscle

Bioengineering strategies for the treatment of peripheral arterial disease

Contact Info

Product

Resources

About